Skip to main content
. 2020 Jul 16;2020:3891436. doi: 10.1155/2020/3891436

Table 2.

Patterns of the use of opioids for pain management in a cohort of 1,129 patients with rheumatoid arthritis in Colombia.

Drug n = 1129 (%) Doses (mean) Interval (no. of doses/day) nDDDa Therapy duration (months) Percent female Mean age (years)
Weak opioids
Codeine 861 76.3 47.7 3 0.47 24.1 0.83 61.5 + 11.6
Tramadol 803 71.1 NA NA NA 21.6 0.83 61.5 + 11.6
Hydrocodone 252 22.3 12.9 3 0.86 35.6 0.85 64.9 + 11.2
Tapentadol 9 0.8 109.7 2 0.27 41.3 0.67 64.2 + 11.9

Strong opioids
Oxycodone 76 6.7 32.3 2 0.43 36.0 0.87 64.4 + 12.8
Morphine 74 6.6 NA NA NA 35.1 0.81 64.2 + 10.8
Hydromorphone 63 5.6 6.7 1 0.33 36.4 0.86 65.7 + 11.4
Methadone 7 0.6 32.4 3 1.29 53.7 100.00 72.3 + 7.9

Presentation most used in bottle with dropper. aRelationship between the mean dose and the defined daily dose. Defined daily dose (DDD): gold standard measuring unit for international drug utilization, monitoring, and research (recommended by the WHO). Each medication has a daily dose defined by the WHO; the calculation presented is the ratio between the average used and the defined daily dose. Being 1, the use of the same dose recommended as DDD.